Zacks.com on MSN1d
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?BeiGene (ONC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report ...
While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...
Tencent Music and Horizon Robotics added to Hang Seng Tech Index, while ZTO Express and BeiGene added to Hang Seng China ...
In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of $286.00. Kelly Shi’s rating is based on a ...
All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback